Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 6/20 | 0.31 |
| ▸ | SMC2 | O95347 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.31 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14016208 | 0.86 | MAP2K1 (0.45) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL1343321 | 0.82 | BRAF (0.39) | SRCCNR2BRD4 | |
| SCHEMBL16803249 | 0.75 | CHEK1 (0.32) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL3426263 | 0.74 | MAP2K1 (0.46) | CSF1RSRCPOLBTSHRMAP2K2 | |
| SCHEMBL13021340 | 0.74 | MAP2K1 (0.38) | CSF1RMAP2K2MAP2K1CHEK1MAPK10 | |
| SCHEMBL3424319 | 0.73 | CSF1R (0.43) | CSF1RSRCPOLBTSHRL3MBTL1 | |
| SCHEMBL1342794 | 0.73 | MAP2K1 (0.39) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL10305791 | 0.73 | MAP2K1 (0.55) | MAP2K2MAP2K1SMC2EGFRCSNK2A2 | |
| SCHEMBL14016189 | 0.73 | MAP2K1 (0.36) | POLBMAP2K2MAP2K1CHEK1MAPK10 | |
| SCHEMBL1343936 | 0.70 | MAP2K1 (0.46) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | MAPK8, MAP3K8, MAP3K2 | CSF1R 2634/4885SRC 74/4885POLB 1544/4885 |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | CSF1R 394/4885SRC 107/4885POLB 1347/4885 |
| US-20100331334-A1 | INHIBITORS OF MEK | NRAS, BRAF, KSR2 | CSF1R 2905/4885SRC 100/4885POLB 934/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | CSF1R 394/4885SRC 107/4885POLB 1347/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | CSF1R 1764/4885SRC 347/4885POLB 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.